New drug cocktail aims to boost leukemia transplant success
NCT ID NCT07644481
First seen Jun 13, 2026 · Last updated Jun 16, 2026 · Updated 1 time
Summary
This study tests a new combination of three chemotherapy drugs (clofarabine, busulfan, and melphalan) given before a stem cell transplant for adults with acute myeloid leukemia (AML) who are in first remission. The goal is to see if this stronger conditioning regimen helps more patients survive longer without the cancer coming back. The trial will enroll 30 adults aged 18 to 60 and track their outcomes for two years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.